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Ghrelin is the natural ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28 amino acid peptide
possessingauniqueacylationontheserineinposition3catalyzedbyghrelinO-acyltransferase(GOAT).Ghrelinstimulatesgrowth
hormone secretion, but also appetite, food intake, weight gain, and gastric emptying. Ghrelin is involved in weight regulation,
obesity, type 2 diabetes, and metabolic syndrome. Furthermore, a better understanding of ghrelin biology led to the identiﬁcation
of molecular targets modulating ghrelin levels and/or its biological eﬀects: GOAT, ghrelin, and GHS-R1a. Furthermore, a recent
discovery, showing the involvement of bitter taste receptor T2R in ghrelin secretion and/or synthesis and food intake, suggested
that T2R could represent an additional interesting molecular target. Several classes of ghrelin-related pharmacological tools for the
treatment of obesity have been or could be developed to modulate the identiﬁed molecular targets.
1.Introduction
Ghrelin, the natural ligand of the growth hormone secre-
tagogue receptor (GHS-R1a) [1], is a potent stimulator of
growth hormone secretion [2, 3]. Moreover, ghrelin is also
an appetite-stimulating hormone inducing food intake and
weight gain in human [4–6], and promoting gastric empty-
ing [7]. Ghrelin is a 28 amino acid peptide predominantly
produced and secreted into the blood stream by the endo-
crine stomach mucosal cells named “X/A like” in rat [8, 9]
and P/D1 cells in humans [10]. Ghrelin has the particularity
to be acylated on the serine in position 3 [1]. During the
processing of preproghrelin, both ghrelin 1-28 and ghrelin
1-27 can result and then are subjected to the acylation of the
h y d r o x y lg r o u po fS e r 3[ 11]. Acylation, a unique peptidic
modiﬁcation, is catalyzed by ghrelin O-acyltransferase, a
member of the membrane-bound O-acyltransferase family,
during the processing of the peptide [2, 3]. The most
frequently acylation is with an octanoyl group (C8:0), and
more rarely with a decanoyl (C10:0) or a decenoyl (C10:1)
group[11].Acylationofghrelincanbeincreasedbyingestion
of either medium-chain fatty acids or medium-chain triacyl-
glycerides [12].
Des-acyl ghrelin represents more than 90% of human
plasma ghrelin immunoreactivity [13]. It remains presently
uncertain if both ghrelin and des-acyl ghrelin, present in
the stomach, are both secreted into the bloodstream via
similar or diﬀerent regulated pathway(s). In the rat stomach,
ghrelin is deacylated by lysophospholipase I [14, 15], and
degraded by N-terminal proteolysis [14, 16]. Shorter half-
life of ghrelin compared to des-acyl ghrelin [17] and plasma
ghrelin deacylation [16, 18] could account for the vast pre-
dominance of des-acyl ghrelin in the circulation. Human
butyrylcholinesterase and other esterase(s), such as platelet-
activating factor acetylhydrolase, and rat carboxylesterase
are responsible for ghrelin desoctanoylation in these species
[16, 19]. Interestingly, butyrylcholinesterase knockout mice
fed with a normal standard 5% fat diet had normal body
weight while mice fed with high-fat diet (11% fat) became
obese. Butyrylcholinesterase was suggested to play a role in
fatcatabolismastheobesephenotypecouldnotbeexplained
by increased ghrelin, caloric intake, or decreased exercise
[20]. The suggested participation of human paraoxonase in
ghrelin deacylation [21] remains controversial [16]. Due to
ghrelin degradation by serum, it is diﬃcult to accurately2 Journal of Obesity
determine the ghrelin level and consequently its physiolog-
ical and pathophysiological roles. In the circulation, des-acyl
ghrelin is mostly present as a free peptide while the vast ma-
jority of acyl ghrelin is bound to larger molecules and in
particular to lipoproteins [19, 21]. The presence of the acyl
group is necessary for ghrelin interaction with triglyceride-
rich lipoproteins and low-density lipoprotein but not high-
density lipoproteins and very high-density lipoproteins.
Besides,ghrelininteractsviaitsN-andC-terminalpartswith
high-densitylipoproteinsandveryhigh-densitylipoproteins.
These data support the transport of acylated ghrelin by
triglyceride-rich lipoproteins and of both ghrelin and des-
acyl ghrelin by high-density lipoproteins and very high-
density lipoproteins [19]. Modiﬁcations to lipoprotein levels
in response to obesity may aﬀect ghrelin transport as well as
free ghrelin levels.
Administration of ghrelin to rats leads to stimulation of
food intake and decrease of energy expenditure, accounting
for body weight increase [6, 22–25]. Intravenous ghrelin
administration in humans also increases appetite and stimu-
lates food intake [6]. Plasma ghrelin levels are negatively cor-
related with BMI and ﬂuctuate in a compensatory manner to
body weight variations [26]. Indeed, plasma ghrelin level is
increased in anorexia nervosa and cachexia, and decreased
in obesity [27] .G h r e l i nl e v e l sd e c r e a s ew i t hw e i g h tg a i n
resulting from overfeeding [28], pregnancy [29], olanzapine
treatment [30], or high fat diet [31]. Central ghrelin admin-
istration to rats submitted to high fat diet does not result
in greater food intake, while increased adiposity in white
adipose tissue occurs [32]. In white adipose tissue, ghrelin
stimulates the gene expression of lipogenic enzymes such as
stearoyl CoA desaturase, acetyl CoA carboxylase, and fatty
acid synthase. These data suggest that central ghrelin simul-
taneously regulates food intake and adipose tissue metabo-
lism through distinct mechanisms [32].
Acute feeding response appears to be mediated by GHS-
R1a [33]. Chronic weight gain eﬀect of ghrelin may be mod-
ulated by both GHS-R1a [34]a sw ella sa na sy etu n i d e n ti ﬁ ed
receptor for ghrelin as both ghrelin and a ghrelin antagonist
induced body weight gain [35]. Nevertheless, further studies
would be required to clarify this issue.
Des-acyl ghrelin has been recently taken into consider-
ation as a modulator of food intake that could act through
an as yet unidentiﬁed receptor [36, 37]. However, des-acyl
ghrelin appears to have controversial eﬀects on food intake
[36, 37]. Indeed, GOAT knockout mice displayed reduced
fat mass despite increased des-acyl ghrelin levels [38]. The
identiﬁcation of speculated des-acyl ghrelin receptors could
deeply increase our knowledge on the mechanisms and
actions sites of this peptide.
High plasma ghrelin levels have been reported in patients
with Prader-Willi syndrome (PWS), a genetic disorder char-
acterized by mental retardation and hyperphagia leading to
severe obesity [39, 40]. In this disorder, ghrelin may be re-
sponsible, at least partially, for the insatiable appetite and the
obesity of the patients.
From the molecular biological point of view, it is inter-
esting to note that both ghrelin and its receptor (GHSR)
genesarelocatedonchromosome3inregions thathavebeen
linked to obesity [41, 42]. Polymorphisms of both ghrelin
and its receptor GHSR1a have been studied in obesity [43–
52]. However, further studies are required to assess unam-
biguously the functional signiﬁcance of these mutations in
the pathogenesis of obesity.
Due to the observed association between plasma ghrelin
levels and insulin levels as well as insulin resistance [53–56],
it was suggested that inhibition of ghrelin secretion and/or
of GHS-R1a could be a useful treatment and/or prevention
for type 2 diabetes. In this respect, data from numerous
studies evaluating the therapeutic implications of ghrelin
on glucose-insulin homeostasis have been recently reviewed
[57, 58].
The involvement of ghrelin in obesity led to the devel-
opment of several ghrelin-related pharmacological tools for
the treatment of obesity. The present review focuses on the
recent advances made in potential clinical applications of
ghrelin in obesity.
2.GhrelinO-Acyltransferase:
APharmacologicalTarget toDecrease
AcylatedGhrelinLevels
Ghrelin O-acyltransferase (GOAT), identiﬁed as being an
orphan membrane-bound O-acyltransferase (MBOAT), cat-
alyzes the addition of an octanoyl group on the serine in
position3[2,3](Figure 1).Ghrelinoctanoylationisessential
for its recognition by GHS-R1a. Two distinct scientiﬁc ap-
proaches led to the identiﬁcation of GOAT. The ﬁrst ap-
proach was based on gene-silencing experiments targeting
a candidate gene encoding an uncharacterized protein con-
taining structural motifs reminiscent of the MBOAT acyl-
transferase family in the human medullary thyroid carci-
noma cells expressing octanoylated ghrelin [2]. The authen-
ticity of the human gene identiﬁed was veriﬁed using RT-
PCR and 5 RACE reactions, and the predicted protein
encoded by the gene was named GOAT. The functional activ-
ity of GOAT, the octanoylation of ghrelin, was demonstrated
by transient transfections of the GOAT cDNA. GOAT was
also shown to acylate ghrelin with fatty acid ranging from
C7toC12.Furthermore,additionalexperimentsrevealedthe
importance of the conserved MBOAT-histidine residue in
position338ofGOATtoitsacylationactivity[2].Thesecond
approach was based on the transfection of rat insulinoma
Ins-1 cells with ghrelin cDNA and subsequently of one at a
time, of the sixteen MBOAT cDNAs [3]. Only one MBOAT
cDNA led to acylated ghrelin production. Furthermore,
mutation of either serine in position 3 of ghrelin or of the
conserved MBOAT-histidine residue in position 338 of
GOAT abolished ghrelin acylation. GOAT exhibits some
speciﬁcity for medium chain fatty acids like octanoate and
proceeds to ghrelin octanoylation before its translocation to
the Golgi where it is cleaved by prohormone convertase 1/3
to form mature ghrelin. This suggested that GOAT is located
in the endoplasmic reticulum [3].
GOAT is a highly hydrophobic protein with eight postu-
lated membrane-spanning helices presenting a high degree
of sequence conservation across vertebrates. GOAT is coex-
pressed with acyl ghrelin in ghrelin-expressing tissues [59].Journal of Obesity 3
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Figure 1: Synthesis, processing, and release of ghrelin by the human endocrine stomach P/D1 cells. Synthesis of ghrelin and acylation
by GOAT occur in the endoplasmic reticulum (ER). Both acyl and des-acyl ghrelin are then secreted into the blood stream by fusion of
secretory vesicles with the plasma membrane. Ghrelin secretion and/or acylation are upregulated following T2R activation. After secretion
of acyl and/or des-acyl ghrelin, acyl ghrelin binds to speciﬁc GHS-R1a receptors. Pharmacological tools tried or currently developed are
indicated and targeted GOAT, T2R, ghrelin, and GHS-R1a.
GOATdisplaysapreferenceforhexanoyl-CoAoveroctanoyl-
C o Aa sa na c y ld o n o r[ 60]. However, the precise mechanism
leading to the entry of acyls-CoA into the endoplasmic ret-
iculum lumen remains unknown. One hypothesis is that
GOAT could possibly bind acyl-CoA and, due to its hy-
drophobic properties, allow the acylation of ghrelin in the
endoplasmic reticulum lumen.
An in vitro biochemical assay for GOAT activity [3]r e -
vealedtheimportanceofproperrecognitionofseveralamino
acids in proghrelin (glycine-1, serine-3, and phenylalanine-
4) for GOAT activity [61].
Fasting and satiation could modulate the activity of
GOAT as ghrelin levels rise before meals [4, 62]a n dd e c r e a s e
with food intake [5]. Moreover, long-term fasting inhibits
ghrelinacylationbutnottotalghrelinsecretionwhereasfeed-
ing suppresses both acyl and des-acyl ghrelin [63]. However,
the eﬀect of fasting and feeding on GOAT mRNA levels
remain unclear [38, 64]. Experimental evidences showed
that GOAT is a leptin-regulated gene [38]. Increased GOAT
mRNA levels in response to long-term chronic malnutrition
[64] could represent the underlying mechanism responsible
for increased acylated ghrelin levels in anorexia nervosa [26].
Dietary lipids are critical for the activation of GOAT, and
consequently ghrelin acylation. Indeed, GOAT knock-out
mice submitted to a diet containing 10% medium-chain tri-
glyceride exhibited lower body weight that can be explained
by lower fat mass compared to wild-type mice [38]. In
addition, GOAT transgenic mice only fed with a medium-
chaintriglyceridessupplementationproducedlargeamounts
of acyl ghrelin [38].
An essential function of ghrelin could be the mainte-
nance of viability during periods of famine. This hypothesis
is supported by the data showing that wild-type and GOAT
knock-out mice submitted to 60% calorie-restricted diet
displayed 30% and 75% body weight loss, respectively [65].
Much work remains to be done to fully understand how
GOAT ﬁts into the control of energy homeostasis. However,
measurement of both GOAT protein levels and GOAT activ-
ity will be crucial to determine its gene expression and func-
tional regulation. Indeed, GOAT knock-out mice represent4 Journal of Obesity
a valuable tool to determine the physiological consequences
of a speciﬁc deﬁciency in acylated ghrelin.
Recently, genetic variation of GOAT was suggested to be
involved in the etiology of anorexia nervosa [66]. It would
be interesting to determine if genetic variation of GOAT
might also be linked to obesity. If this proves to be the case,
personalized medicine targeting GOAT could be envisioned
as a novel therapeutic approach for the treatment of obesity.
Pharmacological tools have been developed to target
the inhibition of GOAT (Figure 1). Indeed, a pentapeptide,
corresponding to the ﬁrst ﬁve N-terminal amino acids of
ghrelin with its C-terminal end amidated competitively in-
hibited GOAT activity through an end-product inhibition
mechanism. The inhibition of GOAT is better achieved when
pentapeptides contain an octanoyl group linked to serine-
3 by an amide linkage [3]. Moreover, GOAT was also in-
hibited by peptide-based bisubstrate analog, GO-CoA-Tat,
in cultured cells, as well as in mice [67]. The design of this
bisubstrate analog was based on the theory that GOAT could
use a ternary complex mechanism to proceed to the linkage
of octanoyl-CoA to ghrelin. The intraperitoneal adminis-
t r a t i o nl e dt or e d u c e dw e i g h tg a i na n di m p r o v e dg l u c o s e
tolerance in wild-type mice but not in ghrelin knock-out
mice [67]. Even though GO-CoA-Tat presents some limita-
tions as a peptide-based drug, it is likely that future synthetic
derivatizationswillmaximizeitspharmacologicalproperties.
In conclusion, GOAT represents an extremely promising
candidate for the development of antiobesity and/or antidi-
abetes drugs. Indeed, it is the unique enzyme responsible for
ghrelin acylation and its modulation would only aﬀect the
physiological process of ghrelin acylation.
3. Neutralization of Ghrelin
Vaccination against ghrelin represents a strategy to block the
eﬀects of ghrelin (Figure 1). Rats immunized with ghrelin
hapten immunoconjugates led to the production of antibod-
ies speciﬁcally directed against acylated ghrelin, and reduced
body weight gain with preferential reduction of fat mass
concomitanttodecreasedfeedingeﬃciency[68].Thehuman
relevance of using vaccination against ghrelin remains un-
certain. Indeed, phase I/II a trial using CYT 009-Ghr Qb
vaccine, from Cytos Biotechnology AG, demonstrated no
weight-loss eﬀect in obese humans despite eﬃcient antibody
response.
High-aﬃnity antiacyl ghrelin speciﬁc monoclonal anti-
bodiesspeciﬁcallybindacylghrelin,dose-dependentlyinhib-
its GHS-R1a activation in vitro, and block ghrelin-induced
food intake in mice in vivo [69].
Neutralization of ghrelin was also achieved using spie-
gelmers, antisense polyethylene glycol-modiﬁed L-oligonu-
cleotides capable of speciﬁcally binding a target molecule
(Figure 1). The spiegelmer NOX-B11-2 decreased food in-
take and body weight in diet-induced obese mice [70–
72]. Another spiegelmer, NOX-B11-3 exerted a long-lasting
action on the inhibition of ghrelin-induced GH release in
rats [73], but did not block the fasting-induced neuronal
activation in the hypothalamic arcuate nucleus [74]. The
neutralization of circulating ghrelin by spiegelmers may be
useful to treat diseases associated with high ghrelin levels
such as PWS characterized by severe obesity. Pﬁzer Inc. has
taken over further development of the NOX-B11 spiegelmers
originally developed by NOXXON Pharma AG.
In conclusion, the therapeutic usefulness of vaccination
againstghrelinandtheuseofghrelinspiegelmersinthetreat-
ment of obesity remain to be proven.
4.GHS-R1a:APharmacologicalTargetto
AntagonizeGhrelin-InducedResponses
4.1. GHS-R1a Antagonists. The inhibition of ghrelin signal-
ing represents an attractive target for pharmacological treat-
ment of type 2 diabetes, obesity, particularly PWS, and
metabolic syndrome. Consequently, several classes of GHS-
R1a antagonists have been developed (Figure 1).
[D-Lys-3]GHRP-6, a peptide GHS-R1a antagonist, de-
creased food intake in lean and obese mice, and reduced
weight gain [70, 75].
Piperidine-substituted quinazolinone derivatives were
identiﬁed as a novel class of small GHS-R1a antagonists
molecules [76]. Phenyl or phenoxy groups are optimal sub-
stituents at position 6 of the quinazolinone core, and the
replacement of phenyl groups in position 2 by small alkyl
substituents were proven to be beneﬁcial [76]. YIL-781, a
piperidine-substituted quinazolinone derivative acting as a
potent GHS-R1a antagonist, improved glucose-stimulated
insulin secretion and reduced food intake and weight loss in
diet-induced obese mice [77].
Some GHS analogs carrying a trisubstituted 1,2,4-tria-
zole structure, such as JMV2866 and JMV2844, behaved
as GHS-R1a antagonists [78, 79]. Recently, additional new
GHS-R1a antagonists of global similar structure have been
identiﬁed using homogenous time-resolved ﬂuorescence-
based assay screening [80].
Optimization of piperazine-bisamide analogs synthesis
ledtopotentGHS-R1aantagonists.Oneoftheseanalogsfea-
tured especially high potency as well as other interesting
pharmacologicalproperties,andinhibitedGHreleaseexvivo
[81].
Several carbohydrazide derivatives were identiﬁed as be-
ing potent and selective GHS-R1a antagonists [82]. Among
these compounds, GSK1614343 was shown to be a potent
competitive antagonist of rat GHS-R1a [83]. Unexpectedly,
GSK1614343 produced an increase in food intake and body
weight in both rats and dogs [84].
BIM-28163 was identiﬁed as a ghrelin antagonist block-
ingghrelin-inducedGHsecretion[85].However,chronicad-
ministration of GHS-R1a antagonist unexpectedly induced
body weight gain [85].
Other GHS-R1a analogs developed to treat weight disor-
ders, including obesity, are also still considered as preclinical
compounds (TZP-301, from Tranzyme Pharma, and EX-
1350, from Elixir Pharmaceuticals) [86].
In conclusions, several classes of GHS-R1a antagonists
have been identiﬁed and could represent an interesting
pharmacological tools for the treatment of obesity as well
as type 2 diabetes and metabolic syndrome. However, long-
term animal and human studies still remain necessary toJournal of Obesity 5
appropriately evaluate the beneﬁcial properties of ghrelin
antagonists in the context of obesity.
4.2. GHS-R1a Inverse Agonists. The high constitutive activity
of GHS-R1a suggested that inverse GHS-R1a agonists,
decreasing its constitutive activity, may be useful for the
treatment of obesity [87, 88]. Long fasting induced, in the
hypothalamus, increased GHS-R1a expression and concom-
itant signaling causing higher appetite and decreased energy
expenditure. Therefore, reduction of the GHS-R1a consti-
tutive activity by an inverse agonist could increase the sen-
sitivity to anorexigenic hormones like leptin or PYY, and
prevent food intake between meals [89].
[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P was
identiﬁed as an inverse agonist on GHS-R1a [90].
In conclusion, GHR-R1a inverse agonists represent inter-
esting pharmacological tool to inhibit GHS-R1a activity
(Figure 1). However, additional studies evaluating the long-
term use of the compounds in animal models are necessary
to elucidate their usefulness in the treatment of obesity and
related diseases in humans.
5.New PotentialPharmacological Target to
Decrease Ghrelin Secretion
Very recently, gavage of bitter taste receptor (T2R) agonists
was shown to increase plasma acyl ghrelin in mice through
the stimulation of α-gustducin, the α-subunit of a trimeric
G-proteincomplexinvolvedintastesignaltransduction[91].
Immunoﬂuorescence studies revealed that the stomach
endocrine cells expressing ghrelin displayed up to 90–95%
colocalization with α-gustducin. Furthermore, gavage of
T2R-agonists increased food intake in wild-type mice but
not in α-gustducin or GHS-R1a knock out mice [91]. It
is presently unclear if the transduction pathways induced
following T2R activation could aﬀect ghrelin acylation by
GOAT and/or ghrelin release.
In conclusion, T2R could represent a new interest-
ing pharmacological target to modulate ghrelin secretion
(Figure 1).Furthermore,thepotentialuseofT2Rantagonists
for the treatment of obesity remains to be evaluated.
6. GeneralConclusions
The involvement of ghrelin in obesity and the better un-
derstanding of ghrelin biology have led to the identiﬁcation
of pharmacological targets and the development of phar-
macological compounds for the treatment of obesity and
related diseases. So far, pharmacological compounds have
been designed to target GOAT, ghrelin, and GHS-R1a. Very
recently, it has been suggested that T2R could also represent
an interesting target in the context of ghrelin and the
treatment of obesity.
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